Search Results - "Bazinet, M"

One year follow-up and HBV RNA / HBcrAg analysis in the REP 301 Trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection by Bazinet, M, Pantea, V, Cebotarescu, V, Cojuhari, L, Jimbei, P, Krawczyk, A, Vaillant, A

Get full text

Effects of nucleic acid polymer therapy alone or in combination with immunotherapy on the establishment of SVR in patients with chronic HBV infection by Al-Mahtab, M, Bazinet, M, Vaillant, A

Get full text

Absence of mutations in the HBsAg “a” determinant during REP 2139 therapy validates serum HBsAg reductions observed in the REP 102 protocol by Usman, Z, Mijočević, H, Karimzadeh, H, Al-Mahtab, M, Bazinet, M, Frishman, D, Vaillant, A, Roggendorf, M

Get full text

Nucleic acid polymer REP2139 monotherapy reveals a short halflife of serum HBsAg in HBeAg+ chronically infected hepatitis B virus patients by Borochov, N, Cotler, S.J, Uprichard, S.L, Al-Mahtab, M, Bazinet, M, Vaillant, A, Dahari, H

Get full text

776 ESTABLISHMENT OF A POTENT ANTI-HBsAg RESPONSE AND DURABLE IMMUNOLOGICAL CONTROL OF VIREMIA WITH SHORT TERM IMMUNOTHERAPY AFTER REP 9AC-INDUCED HBsAg SEROCLEARANCE IN CHRONIC HBV INFECTION by Al-Mahtab, M, Bazinet, M, Vaillant, A

Get full text

LO2 : Significant reduction of HBsAg and HDV RNA by the nucleic acid polymer REP 2139 in caucasian patients with chronic HBV/HDV co-infection by Bazinet, M, Pantea, V, Cebotarescu, V, Cojuhari, L, Jimbei, P, Vaillant, A

Get full text

Data driven optimization of sexual assault case processing by Bazinet, M., Larose, J., Noël, S., Comte, J., Primeau, M., Lapointe, M., Paquet, C., Landry, R., Croteau, L., Gingras, F.

“…In recent years, several forensic laboratories have noted an increase in the number of sexual assault cases submitted for testing, often leading to longer…”
Get full text

Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infection by Bazinet, M, Pantea, V, Placinta, G, Moscalu, I, Cebotarescu, V, Cojuhari, L, Jimbei, P, Iarovoi, L, Smesnoi, V, Musteata, T, Jucov, A, Krawczyk, A, Vaillant, A

Get full text

P0659 : Cytokine responses in chronic hepatitis B patients dosed with the nucleic-acid polymer REP2139-Ca by Stelma, F, Vaillant, A, Jansen, L, Sinnige, M.J, van Leeuwen, E.M, Kootstra, N.A, Bazinet, M, Al-Mahtab, M, Reesink, H.W

Get full text

O114 : Serum HBV-RNA levels decline significantly in chronic hepatitis B patients dosed with the nucleic-acid polymer REP2139-CA by Jansen, L, Vaillant, A, Stelma, F, Kootstra, N.A, Bazinet, M, Al-Mahtab, M, Reesink, H.W

Get full text

Update on the Safety and Efficacy of REP 2139 Monotherapy and Subsequent Combination Therapy with Pegylated Interferon Alpha-2A in Caucasian Patients with Chronic HBV/HDV Co-Infection by Bazinet, M, Pantea, V, Cebotarescu, V, Cojuhari, L, Jimbei, P, Albrecht, J, Schmid, P, Krawczyk, A, Karimzadeh, H, Roggendorf, M, Vaillant, A

Get full text

Polychlorinated biphenyls (PCBs) contamination and aryl hydrocarbon receptor (AhR) agonist activity of Omega-3 polyunsaturated fatty acid supplements: Implications for daily intake of dioxins and PCBs by Bourdon, J.A., Bazinet, T.M., Arnason, T.T., Kimpe, L.E., Blais, J.M., White, P.A.

“…Omega-3 polyunsaturated fatty acid (n-3 PUFA) rich oils derived primarily from fish are frequently consumed as supplements. Due to the tendency of persistent…”
Get full text

75 REP 9AC IS A POTENT HBSAG RELEASE INHIBITOR WHICH CLEARS SERUM HBSAG AND ELICITS SVRS IN PATIENTS WITH CHRONIC HEPATITIS B by Al-Mahtab, M, Bazinet, M, Vaillant, A

Get full text

Value of systematic transition zone biopsies in the early detection of prostate cancer by Bazinet, M, Karakiewicz, P I, Aprikian, A G, Trudel, C, Aronson, S, Nachabé, M, Péloquin, F, Dessureault, J, Goyal, M, Zheng, W, Bégin, L R, Elhilali, M M

“…A prospective study was done to determine the value of performing 2 systematic transition zone biopsies in addition to systematic sextant peripheral zone…”
Get more information

Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma by Bazinet, Michel, Zheng, Wei, Bégin, Louis R., Aprikian, Armen G., Karakiewicz, Pierre I., Elhilali, Mostafa M.

“…Neoadjuvant androgen ablation (NAAA) causes significant cytoarchitectural changes in both benign and malignant prostatic epithelial cells that may contribute…”
Get full text

Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells by Aprikian, A G, Han, K, Chevalier, S, Bazinet, M, Viallet, J

“…Bombesin and gastrin-releasing peptide (GRP) are potent neuropeptides expressed by prostate cancer neuroendocrine cells and are related to the progression of…”
Get more information

Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co-infection: 18 month follow-up results from the REP 301-LTF study by Bazinet, M., Pantea, V., Cebotarescu, V., Cojuhari, L., Jimbei, P., Vaillant, A.

Get full text

FRI-326 - Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co-infection: 18 month follow-up results from the REP 301-LTF study by Bazinet, M., Pantea, V., Cebotarescu, V., Cojuhari, L., Jimbei, P., Vaillant, A.

Get full text

Neuroendocrine differentiation in metastatic prostatic adenocarcinoma by Aprikian, A G, Cordon-Cardo, C, Fair, W R, Zhang, Z F, Bazinet, M, Hamdy, S M, Reuter, V E

“…Neuroendocrine differentiation of prostatic adenocarcinoma has received considerable attention in recent years. The objectives of this study were to…”
Get more information

Modeling serum HBsAg, HBV DNA and transaminase kinetics during REP 2139 monotherapy in chronic HBeAg+ HBV infection by Shekhtman, L., Borochov, N., Cotler, S., Hershkovich, L., Uprichard, S., Al-Mahtab, M., Bazinet, M., Vaillant, A., Dahari, H.

Get full text